Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
This is particularly true among men older than 50, who warrant greater monitoring.
This holds true even for those with highly severe liver disease.
The trial tested 16 and 24 weeks of grazoprevir/uprifosbuvir/ruzasvir among those with genotype 1 who had failed a previous treatment.
Compared with the standard treatment, this new method also appears to be safer—but it doesn’t offer a longer life.
Some countries, such as Australia and the United Kingdom, permit people to import generic drugs for personal use.
A small proof-of-concept study of GS-0976 inhibited de novo lipogenesis (DNL) and reduced liver fat and stiffness.
BMS-986036, a retooled version of the non-alcoholic steatohepatitis drug FGF21, showed promise in a Phase II trial.
The actual cause was discovered during the failed trial of a non-alcoholic steatohepatitis (NASH) treatment.
Researchers retooled the non-alcoholic steatohepatitis treatment FGF19 to yield a variant dubbed NGM282.
The risk for death from cirrhosis itself is particularly high.
A new World Health Organization (WHO) report is the most definitive account to date of the global impact of hepatitis B and C.
Among people with hep C and compensated cirrhosis, this risk reduction was particularly stark after six years of follow-up.
The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.
The investigational glecaprevir/pibrentasvir was tested among people with genotype 3 of hepatitis C virus who did not have cirrhosis.
Real-world data showed Merck’s hep C regimen performed well among a population with genotypes 1 or 4 and multiple other health conditions.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.